Bryan Garnier - MedMen Enterprises Inc. (MMEN) MEDMEN ENTERPRISES - SELL vs. NEUTRAL | CAD0.35 vs. 1.2 Operations are being turned around

Report

Bryan Garnier

Nikolaas Faes

MEDMEN ENTERPRISES - SELL vs. NEUTRAL | CAD0.35 vs. 1.2 Operations are being turned around

MEDMEN ENTERPRISES - SELL | CAD0.14 vs. CAD0.35 (-58%)
The Flight of Icarus

MedMen is unlikely to make money any time soon
GGP has MedMen over the barrel

01/06/2020 4 EN

Underlying

MedMen Enterprises Inc.

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Nikolaas Faes

Other Reports on these Companies

Independent Investment Research

Monthly LMI Update Independent Investment Research

Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked. This compares to the total dividends of 5 cents per share in FY20. The Board has confirmed that, in...

August 6, 2021 August 6, 2021 10 EN

Bryan Garnier

Cannabis | Drop of coverage: MEDMEN, IANTHUS, FLOWR

June 25, 2021 June 25, 2021 3 EN

On the shelves now: Consumer Weekly #62

In this Consumer Weekly newsletter, we provide a brief overview of the key factors affecting our Consumer coverage, from Luxury & Consumer goods to Retail & E-commerce and Food & Ingredients. This week, we look at how Trump's trade war is negatively impacting US consumer sentiment. Happ

16h / 54m 16h / 54m 1 EN

Clement Genelot

Clement Genelot

HelloFresh: no rerating without timing for meal-kit stabilisation

Post-FY 2024 results and disappointing FY 2025 guidance, we have cut our PT from EUR10 to EUR8.5. We find it hard to board a plane (i.e. the HelloFresh equity story) with a faulty main engine (i.e. core meal-kit expected to continue declining until at least 2027 in our model). Only a clear timing f

17h / 8m 17h / 8m 1 EN

Clement Genelot

Clement Genelot

Tesco: can Asda really revive the price war in the UK?

As Asda's new leader sends the group to the front line with a very aggressive and risky price repositioning plan, we struggle to identify a scenario whereby Asda would have enough ammunition to hold out. The feared scenario of a revived price war in the UK is not (yet) here, but we are adopting a s

17h / 10m 17h / 10m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

MEDMEN ENTERPRISES - SELL vs. NEUTRAL | CAD0.35 vs. 1.2 Operations are being turned around

Monthly LMI Update Independent Investment Research

Cannabis | Drop of coverage: MEDMEN, IANTHUS, FLOWR

On the shelves now: Consumer Weekly #62

HelloFresh: no rerating without timing for meal-kit stabilisation

Tesco: can Asda really revive the price war in the UK?

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe